Findings

What do systematic reviews say?

8 questions · 8 findings · 6 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 37.5%GRADE not reported 1 · 12.5%Very low 2 · 25%Low 1 · 12.5%Moderate 1 · 12.5%High 0 · 0%

Adjuvant chemotherapy vs no chemotherapy

Serious adverse events · people with resectable cholangiocarcinoma

It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).

1 finding from 1 review

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
RR 17.82 [2.43, 130.82]
1 study · 219 participants
Very low

Adjuvant chemotherapy vs no chemotherapy

Non‐serious adverse events · people with resectable cholangiocarcinoma

The review found no eligible studies for this question.

1 finding from 1 review

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Surgically‐related severe adverse effects (grade 3+) ‐ postoperative G3+ events (within 30 days of surgery) · women with advanced ovarian epithelial cancer

Neoadjuvant chemotherapy prior to interval surgery (NACT) probably leads to lower surgically‐related severe adverse effects (grade 3+) ‐ postoperative… compared with surgery followed by chemotherapy (PDS) (moderate certainty).

1 finding from 1 review

Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
RR 0.22 [0.13, 0.38]
2 studies · 435 participants
Moderate

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

Adverse events · stage III and IV cutaneous melanoma

The review found no eligible studies for this question.

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Severe adverse events and toxicity · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).

1 finding from 1 review

Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
RR 1.32 [0.47, 3.71]
1 study · 118 participants
Low

GnRH agonist‐antagonist cotreatment plus chemotherapy vs chemotherapy alone

Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy

1 finding from 1 review

Adjuvant gonadotropin‐releasing hormone analogues for the prevention of chemotherapy‐induced premature ovarian failure… 2019 · Cochrane Headline outcomes only
no estimate extracted
0 participants
GRADE not reported

Adjuvant S‐1 vs gemcitabine

Serious adverse events · people with resectable cholangiocarcinoma

1 finding from 1 review

Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 70 participants
Very low

Intervention not reported

Adverse events · women with stage I/II epithelial ovarian cancer

The review found no eligible studies for this question.

1 finding from 1 review

Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found